Nature Communications (Aug 2021)

Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis

  • Rosa Andres-Ejarque,
  • Hira Bahadur Ale,
  • Katarzyna Grys,
  • Isabella Tosi,
  • Shane Solanky,
  • Chrysanthi Ainali,
  • Zeynep Catak,
  • Hemawtee Sreeneebus,
  • Jake Saklatvala,
  • Nick Dand,
  • Emanuele de Rinaldis,
  • Anna Chapman,
  • Frank O. Nestle,
  • Michael R. Barnes,
  • Richard B. Warren,
  • Nick J. Reynolds,
  • Christopher E. M. Griffiths,
  • Jonathan N. Barker,
  • Catherine H. Smith,
  • Paola Di Meglio,
  • the PSORT Consortium

DOI
https://doi.org/10.1038/s41467-021-25066-9
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Biomarkers to indicate potential response to biologic therapeutics are needed for patients with psoriasis. Here the authors show that phosphorylation of NFκBp65 in cDC2 before therapy is an indication of non-response to the anti-TNF therapy adalimumab in patients with psoriasis.